We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Denies Vanda Petition on Generics of Schizophrenia Drug Fanapt
FDA Denies Vanda Petition on Generics of Schizophrenia Drug Fanapt
The FDA rejected Vanda Pharmaceuticals petition to delay the approval of ANDAs referencing its schizophrenia therapy Fanapt until its three-year market exclusivity for a new indication expires.